515135-47-4Relevant academic research and scientific papers
HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2
-
Paragraph 0316, (2018/03/25)
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these
PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
-
Paragraph 0248; 0249, (2018/05/03)
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these
PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
-
Page/Page column 48; 49, (2014/12/12)
The present invention relates to 6-amino-7-deaza-purine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular RET family kinases. The present
p38α mitogen-activated protein kinase inhibitors: Optimization of a series of biphenylamides to give a molecule suitable for clinical progression
Aston, Nicola M.,Bamborough, Paul,Buckton, Jacqueline B.,Edwards, Christopher D.,Holmes, Duncan S.,Jones, Katherine L.,Patel, Vipulkumar K.,Smee, Penny A.,Somers, Donald O.,Vitulli, Giovanni,Walker, Ann L.
experimental part, p. 6257 - 6269 (2010/03/31)
p38α MAP kinase is a key anti-inflammatory target for rheumatoid arthritis, influencing biosynthesis of pro-inflammatory cytokines TNFα and IL-1β at a translational and transcriptional level. In this paper, we describe how we have optimized a series of no
Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity
Angell, Richard,Aston, Nicola M.,Bamborough, Paul,Buckton, Jacky B.,Cockerill, Stuart,deBoeck, Suzanne J.,Edwards, Chris D.,Holmes, Duncan S.,Jones, Katherine L.,Laine, Dramane I.,Patel, Shila,Smee, Penny A.,Smith, Kathryn J.,Somers, Don O.,Walker, Ann L.
scheme or table, p. 4428 - 4432 (2009/04/06)
The biphenyl amides (BPAs) are a novel series of p38α MAP kinase inhibitor. The optimisation of the series to give compounds that are potent in an in vivo disease model is discussed. SAR is presented and rationalised with reference to the crystallographic binding mode.
BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS
-
Page/Page column 51, (2008/06/13)
New bicyclic derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.
P-38 kinase inhibitors
-
Page/Page column 16, (2008/06/13)
Compounds and compositions for modulating the activity of p38 kinases are provided, including p38α and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder are also provided.
HETEROARYL SUBSTITUTED BIPHENYL DERIVATIVES AS P38 KINASE INHIBITORS
-
Page/Page column 26, (2010/02/07)
Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
